H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:) A/S on Monday, setting a price target of $49, which is approximately 13.79% above the present share price of $43.06.

Selvaraju expects Genmab A/S to post earnings per share (EPS) of $0.00 for the first quarter of 2021.

The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Genmab, with an average price target of $42.5.
The analysts price targets range from a high of $49 to a low of $34.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.72 billion and a net profit of $858 million. The company’s market cap is $28.22 billion.

According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 38.8% and a 77.29% success rate.

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.